Executive summary
Across the provided literature, fisetin and quercetin repeatedly appear as bioactive flavonoids whose real-world performance is constrained by formulation-limited exposure, with multiple sources explicitly describing poor aqueous solubility and low measurable bioavailability for conventional preparations or solutions/suspensions.[1–4] Multiple nano- and lipid-based approaches (liposomes, nanoliposomes, polymeric micelles, nanosuspensions, nanoemulsions, nanocochleates, SNEDDS) are presented as practical strategies to improve systemic exposure and/or absorption kinetics, often with large quantitative gains in AUC or relative bioavailability.[3–9] The strongest human pharmacokinetic signal in the dataset is a hybrid micelle-in-hydrogel fisetin system (FF-20), which increased fisetin AUC0–12h 26.9-fold and Cmax from 9.97 ng/mL to 238.2 ng/mL compared to an unformulated comparator, while also extending the time window over which fisetin was quantifiable in plasma.[4]
Senolytic rationale
Within this dataset, fisetin is explicitly framed as a senotherapeutic or senolytic flavonoid in multiple sources, including a study that selected fisetin specifically as a “well-studied senotherapeutic drug” for testing in liposomes and a review statement that fisetin has “senolytic effects.”[10, 11] Preclinical in vivo evidence referenced in the provided excerpts states that, among ten natural flavonoids tested in vivo, fisetin was reported as “the most potent senolytic compound,” reducing senescence markers in progeroid and old mice.[12] However, the only direct senescence-model experiment included in the dataset (doxorubicin-induced senescence in A549 and WI38 cells) found no selective senolysis for free fisetin or fisetin-loaded liposomes in viability assays, while still observing senomorphic modulation of SASP cytokines IL-6 and IL-8 by ELISA.[10]
Liposomal encapsulation strategies
Liposomal fisetin is represented by multiple preparation and characterization approaches, including a thin-layer / thin-film method using defined phospholipids and cholesterol, as well as a thin-film evaporation nanoliposome platform with optional hyaluronic-acid coating for stability and digestion-phase micellarization outcomes.[10, 13] In one in vitro senescence study, liposomes were prepared by mixing DOPC, DSPE, and cholesterol in organic solvent, forming a lipid film, rehydrating in HEPES buffer, and extruding through polycarbonate membranes down to 100 nm to obtain uniform liposomes.[10] Those liposomes exhibited Z-average 115.9 ± 0.9 nm (PDI 0.155 ± 0.004) and ζ-potential −20.3 ± 0.6 mV when empty, while fisetin encapsulation reduced size to 95.1 ± 1.0 nm (PDI 0.178 ± 0.008) and shifted ζ-potential to −11.6 ± 1.2 mV, with an encapsulation efficiency of 13.68%.[10]
A separate nanoliposome system used lecithin and fisetin at a 25:1 mass ratio with fisetin concentration 0.8 mg/mL, produced by thin-film evaporation and ultrasonication (2 min at 40 W/cm²), yielding ~80 nm rectangular nanoliposomes with PDI around 0.3.[13] Hyaluronic acid (HA) coating was prepared by dissolving HA in phosphate buffer and mixing with nanoliposomes at a 1:10 volume ratio with overnight stirring, and the HA molecular weight affected encapsulation efficiency (90–95% at 3/35/90–100 kDa, decreasing to 79% at 150–250 kDa and 74% at 1000–1500 kDa).[13]
Polymeric and self assembled micelles
Polymeric micelles are explicitly described in the dataset as nanoscale core/shell assemblies formed by amphiphilic block copolymers, and multiple quercetin micelle systems provide quantitative oral PK improvements.[2, 5, 7] In rats, an MPEG-b-PLLA quercetin micelle (prepared by thin-film hydration) had particle size 88.5 ± 2.6 nm with PDI 0.13 ± 0.04, encapsulation efficiency 82.5 ± 2.1%, and zeta potential −8.72 ± 1.03 mV.[7] This micelle increased AUC0–∞ from 4633.71 ± 557.67 h·ng/mL (aqueous suspension) to 41677.10 ± 4573.95 h·ng/mL and was explicitly reported as a 9-fold increase in relative oral bioavailability, with higher Cmax (1920.83 ± 250.14 ng/mL vs 628.67 ± 64.66 ng/mL) and delayed Tmax (7.3 ± 1.6 h vs 3.0 ± 1.1 h).[7]
A second quercetin micelle approach used Soluplus micelles prepared by modified film dispersion (soluplus plus F127), in which a 7% theoretical drug loading produced particle size 79.00 ± 2.24 nm with PDI 0.154 ± 0.044, encapsulation efficiency 95.91% ± 4.05%, and zeta potential −17.10 ± 2.30 mV.[2] In beagle dogs, these micelles extended detectability of quercetin from 24 h (free drug) to 48 h (micelle) and increased Cmax from 5.24 μg·mL−1 to 7.56 μg·mL−1, while reporting a half-life 2.19-fold longer than pure quercetin.[2]
Solid lipid and nanoparticle platforms
Beyond micelles and liposomes, the dataset includes multiple nanoparticle platforms spanning polymeric nanoparticles (PLGA), protein nanoparticles (BSA-based), chitosan ionic-gelation nanoparticles, and nanosuspensions/nanocrystals, each with detailed size and encapsulation metrics.[1, 14–16] PLGA nanoparticles for fisetin were developed for intravenous-oriented evaluation, with an example formulation (NP4) reported at ~330 nm mean particle size, ζ-potential −7.2 mV, PDI 0.25, encapsulation efficiency 83.58%, and drug loading 13.93%.[17] A second PLGA nanoparticle system for fisetin (FST-NP) reported mean size 187.9 nm, PDI 0.121, ζ-potential −29.2 mV, and encapsulation efficiency 79.3%, and it produced 4.9×, 3.2×, and 2.3× higher permeation than suspension in an everted gut sac model across duodenum/jejunum/ileum.[15]
Folate-targeted fisetin nanoparticles (FFANPs) were reported as monodisperse spherical particles of 150 nm with PDI 0.117 and high encapsulation efficiency (92.36% ± 3.84) with loading capacity 8.39% ± 3.04, supporting a receptor-targeting paradigm rather than an oral exposure paradigm within the provided excerpt.[14] Chitosan/TPP ionic-gelation fisetin nanoparticles (FNPs) had average size 363.1 ± 17.2 nm and ζ-potential +17.7 ± 0.1 mV, with encapsulation efficiency 78.79 ± 7.7% and loading capacity 37.46 ± 6.6%.[1]
Self emulsifying and nanoemulsion systems
The dataset describes both SNEDDS concepts at the definition level and concrete nanoemulsion systems with in vivo PK outcomes for fisetin, emphasizing formulation-driven absorption kinetics and dose efficiency in disease models.[5, 6] For fisetin, an optimized nanoemulsion formulation (nanoemulsion 9) was composed of Miglyol 812 N (10%), Labrasol (10%), Tween 80 (2.5%), Lipoid E80 (1.2%), glycerol (2.25%), NaOH (0.1N) to pH 7, and water to 100%, with nanoparticle diameter 146 ± 3 nm and very low PDI 0.015 reported for the Miglyol-containing preparation.[6] The same nanoemulsion family was also characterized as having droplet diameter 153 ± 2 nm, negative ζ-potential −28.4 ± 0.6 mV, and PDI 0.129, and the nanoemulsion was reported stable at 4 °C for 30 days with phase separation at 20 °C.[6]
Pharmacokinetically, intravenous administration of this fisetin nanoemulsion at 13 mg/kg was reported to show no significant difference in systemic exposure compared to free fisetin, while intraperitoneal administration produced a 24-fold increase in relative bioavailability compared to free fisetin, attributed to faster absorption as reflected by a shorter mean absorption time (MAT 1.97 h vs 5.98 h).[6]
For quercetin, one SNEDDS study described an optimized nanoemulsifying formulation using triacetin as oil phase, Tween 20 as surfactant, and ethanol as co-surfactant, with an NE4 particle size of 11.96 nm and reported high drug content (~97.98% to 100.88%).[18]
Quantitative bioavailability gains
The literature excerpted here supports a consistent pattern: nano/lipid delivery systems can shift exposure by multiples relative to conventional solutions, suspensions, or unformulated comparators, with fold-changes reported directly in multiple independent studies and reviews.[3–5, 7–9] The table below consolidates reported fold-gains and core PK endpoints exactly as stated in the sources, using AUC-based relative bioavailability where available.
| Flavonoid | System | Model | Key quantitative gain | PK details reported |
|---|---|---|---|---|
| Fisetin | Hybrid-FENUMAT micelle-in-hydrogel (FF-20) | Healthy volunteers (single dose) | AUC0–12h 26.9-fold higher vs UF[4] | Cmax 238.2 ng/mL (FF-20) vs 9.97 ng/mL (UF); Tmax 1.24 h vs 0.88 h; t1/2 1.51 h vs 1.14 h; fisetin quantifiable up to 8 h vs 2 h[4] |
| Fisetin | Nanoemulsion | Mice (intraperitoneal) | 24-fold higher relative bioavailability vs free fisetin[6] | Faster absorption (MAT 1.97 h vs 5.98 h); similar exposure vs free for i.v. dosing (superimposable curves; similar Cmax/AUC/t1/2)[6] |
| Fisetin | Nanocochleates (review summary) | In vivo (route specified as sustained release context) | Bioavailability improved up to 141 times[5] | Reported as sustained release from the prepared complex[5] |
| Fisetin | Liposomal system (review summary) | In vivo (intraperitoneal) | Bioavailability improved 47 times[5] | Route specified as intraperitoneal injection[5] |
| Quercetin | MPEG-b-PLLA micelle | SD rats (oral) | Relative oral bioavailability 9-fold vs aqueous suspension (AUC-based)[7] | AUC0–∞ 41677.10 ± 4573.95 vs 4633.71 ± 557.67 h·ng/mL; Cmax 1920.83 ± 250.14 vs 628.67 ± 64.66 ng/mL; Tmax 7.3 ± 1.6 vs 3.0 ± 1.1 h[7] |
| Quercetin | LipoMicel liquid micelle matrix | Healthy volunteers (crossover) | 8-fold AUC and 9-fold Cmax increases vs free quercetin[8] | Cmax 182.85 ng/mL at Tmax 0.5 h; AUC for phytosome slightly higher than LipoMicel in the same study report[8] |
| Quercetin | Casein nanoparticles with HP-β-CD | Wistar rats (oral) | Relative oral bioavailability close to 37% (nine times higher than control solution); control oral solution about 4% bioavailability[3] | Plasma levels observed up to 72 h for Q-HPCD-NP; AUC 61 μg·h/mL ~10-fold higher than oral solution[3] |
| Quercetin | Nanosuspensions with stabilizers and metabolic inhibitors | SD rats (oral) | Absolute bioavailability increased up to 23.58% vs 3.61% for water suspension (highest group SPC-Pip-Que-NSps)[9] | AUC0–∞ increases reported as 6.5× (SPC-Pip) and 4.3× (TPGS) vs suspension in-text with AUC values provided[9] |
| Quercetin | Nanocrystal self-stabilized Pickering emulsion | SD rats (oral) | AUC0–t increased 2.76× vs coarse powder and 1.38× vs nanocrystals[19] | Tmax shortened to 1.75 ± 1.26 h vs 3.33 ± 1.63 h (coarse) and 2.96 ± 0.17 h (NC); Cmax 6.06 μg·mL−1 (NSSPE) vs coarse powder (2.41× relationship stated)[19] |
First pass and absorption constraints
While the dataset does not directly quantify hepatic metabolism pathways, several studies operationally demonstrate that formulation can control the absorption process and time course, including faster absorption (shorter MAT) for intraperitoneally administered fisetin nanoemulsion and prolonged detectability for human FF-20 compared with an unformulated comparator.[4, 6] For quercetin, multiple oral nanocarriers prolong systemic residence, including casein nanoparticles that maintained measurable plasma levels up to 72 h (vs 24 h for the non-cyclodextrin nanoparticle condition) and Soluplus micelles that extended detection to 48 h compared to 24 h for free drug in dogs.[2, 3] The data also show that nanocarriers can shift Tmax in either direction depending on system architecture, such as delayed Tmax in MPEG-b-PLLA quercetin micelles (7.3 h vs 3.0 h) and shortened Tmax in the quercetin Pickering emulsion (1.75 h vs 3.33 h).[7, 19]
Analytical validation
The dataset provides extensive evidence that quantitative evaluation of flavonoid nanoformulations relies heavily on liquid chromatography (HPLC/UPLC) and LC-MS/MS, with additional use of UV-Vis absorbance and fluorescence methods for formulation characterization and content assays.[1, 4, 7, 9, 10, 13] In human fisetin pharmacokinetics for FF-20, fisetin and its metabolite geraldol were quantified using UPLC-ESI-MS/MS (QTRAP) in negative-ion MRM mode after acetonitrile extraction and filtration, and fisetin content was also measured by validated HPLC analysis.[4] In rat quercetin micelle pharmacokinetics, a triple quadrupole LC-MS/MS method quantified quercetin by MRM transition m/z 301.1 → 151.0 with chromatographic separation on an Agilent Eclipse-C18 column under an isocratic water/methanol mobile phase.[7]
Several formulation papers used HPLC-UV or HPLC-DAD for content and release/permeation assays, including fisetin nanoemulsion quantification by reversed-phase HPLC with UV detection at 360 nm and quercetin-loaded casein nanoparticle quantification by HPLC-UV with DAD at 370 nm.[3, 6] Some systems used UV-Vis spectrophotometry for fisetin or quercetin concentration estimation (e.g., fisetin at 364 nm for chitosan nanoparticles; quercetin at 374 nm for SNEDDS dissolution/drug content), and one liposomal fisetin study quantified fisetin concentration by spectrofluorometry with excitation/emission at 418/486 nm.[1, 10, 18]
Senescence and efficacy outcomes
Direct senescence-model outcomes in the dataset are currently dominated by one in vitro study testing fisetin and fisetin-loaded liposomes in doxorubicin-induced senescence models, in which neither free fisetin nor fisetin-loaded liposomes produced selective apoptosis of senescent over non-senescent cells in viability assays.[10] The same study nonetheless reported senomorphic activity evidenced by reduced IL-6 and IL-8 secretion in senescent cells and framed both free and liposomal fisetin as modulating the SASP by ELISA analysis.[10] Complementing these findings, an external in vivo senolytic claim included in the excerpts states that fisetin was reported as the most potent senolytic among ten flavonoids tested in vivo, reducing senescence markers in progeroid and old mice, but without formulation details in the provided quote set.[12]
Outside of senescence endpoints, multiple nanoformulations demonstrate disease-model efficacy consistent with exposure improvements, including fisetin nanoemulsion achieving 53% tumor volume reduction at 36.6 mg/kg versus a ~6-fold higher free-fisetin dose (223 mg/kg) for similar tumor growth inhibition in Lewis lung carcinoma-bearing mice.[6] Other non-senescence efficacy examples include fisetin nanosuspension improving memory and learning and reducing MAO-A levels in Aβ(25–35)-induced dementia mice, and fisetin chitosan nanoparticles reducing inflammatory cytokine mRNA (TNF-α and IL-6) and increasing IL-10 in IL-1β-pretreated chondrocytes while preventing reduction of cartilage-related transcripts (Sox-9 and COL2).[1, 16]
Translational status
The dataset includes multiple human volunteer bioavailability studies for both fisetin and quercetin formulations, providing direct translational relevance for exposure enhancement claims.[4, 8] For fisetin, a randomized, double-blinded, cross-over design in 15 healthy volunteers compared a 1000 mg dose of UF to 1000 mg FF-20 (delivering 192 mg fisetin) with a 10-day washout, enabling direct within-subject PK comparison that showed markedly higher AUC and Cmax for FF-20 and longer quantifiable duration for fisetin in plasma.[4] For quercetin, a non-blinded crossover study in 12 healthy adult volunteers evaluated three quercetin products and reported that the LipoMicel liquid micelle matrix achieved 8-fold AUC and 9-fold Cmax increases compared to free quercetin, with Cmax of 182.85 ng/mL at Tmax 0.5 h.[8]
Gaps and future directions
Within the confines of the provided evidence, a key gap is the limited coupling of oral bioavailability improvements to direct senescence clearance endpoints (e.g., selective elimination of senescent cells), because the only explicit senescence-model experiment here showed senomorphic SASP reduction without senolytic selectivity for both free fisetin and fisetin-loaded liposomes.[10] Another gap is that some platforms report substantial improvements in bioaccessibility or permeation (e.g., fisetin nanoliposomes increasing bioaccessibility to 88.9–92.5% versus 7.2% in bulk oil, and PLGA fisetin nanoparticles increasing intestinal permeation up to 4.9× in an everted gut sac model) without parallel in vivo systemic PK confirmation in the excerpts provided here.[13, 15]
A practical future direction implied by the evidence is tighter integration of formulation characterization with validated bioanalytical measurement, since the dataset shows a broad methodological spectrum—from LC-MS/MS and UHPLC-HRMS in clinical PK to UV-Vis assays for encapsulation or dissolution in formulation screening—suggesting that harmonized quantitation strategies could improve cross-study comparability.[1, 4, 8, 18] A second future direction is formulation selection tailored to desired absorption profiles, because the studies show both delayed and accelerated Tmax depending on carrier type (e.g., MPEG-b-PLLA micelles delaying Tmax vs Pickering emulsions shortening it), implying that “best” formulation may differ by therapeutic objective and dosing window.[7, 19]
